Mylan launches generic Depakote ER in USA
The USA's largest generic drugmaker Mylan has started shipping a low-cost version of Abbott Laboratories' Depakote (divalproex sodium extended-release), an anti-seizure drug with almost blockbuster sales, after the US Food and Drug Administration approved its Abbreviated New Drug Application.
As the first company to file for approval of a generic version, Mylan has been awarded six months of marketing exclusivity for the 500mg strength, though not the 250mg dose, which it is also shipping immediately.
US health care major Abbott Laboratories' Depakote ER had domestic sales of approximately $901.0 million for the 12 months to September 30, 2008. $789.0 million of this was generated by the 500mg strength and $112.0 million came from the 250mg version.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze